Corporate Information – Page 8 – Alligator Bioscience

2023-08-17

The exercise period for Alligator’s warrants of series TO 6 begins today

Today, on August 17, 2023, the exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) ("Alligator" or the ...

2023-08-17

Lund, Sweden, August 17, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the resignation of Malin Carlsson as th ...

2023-08-15

Alligator Bioscience AB (publ) (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series TO 6 (the “warran ...

2023-07-31

Technical Feasibility achieved in second collaboration project triggering new milestone payment to Alligator Collaboration aims to discover ...

2023-07-11

Presentation highlights very promising interim efficacy analysis from mitazalimab OPTIMIZE-1 Phase 2 study in pancreatic cancer Latest analy ...

2023-07-05

Alligator Bioscience AB (publ) today announces that Anette Sundstedt, PhD, Principal Scientist at Alligator, has been appointed as employee ...

2023-06-26

Regulatory

Continued follow-up on the futility analysis cohort (23 patients) showed deepening of tumor responses and an increase in Objective Response ...

2023-06-13

June 27, 2023 – 9:00 AM ET / 3:00 PM CET Featuring Dr. Zev Wainberg from UCLA Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) ...

2023-06-05

Mitazalimab achieved 52% Objective Response Rate when combined with mFOLFIRINOX in 1st line pancreatic cancer and passed the futility analys ...